Integrating MRI Volume and Plasma p ‐Tau217 for Amyloid Risk Stratification in Early Stage Alzheimer’s Disease

Abstract

Background: Accurately detecting amyloid‐β (Aβ) accumulation is critical for identifying patients with early stage Alzheimer’s disease (AD) who may benefit from Aβ‐targeted therapies. While Aβ positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers are reliable, their high cost and invasiveness limit widespread use.

The paper